Clinical Report: Global and National Research Trends in Targeted Therapy for Bladder Cancer

Overview

This bibliometric review analyzes the research trends in targeted therapy for bladder cancer (BC) over the past thirty years. It highlights the increasing publication volume, key research hotspots, and the leading countries and institutions contributing to this field.

Background

Bladder cancer is a prevalent malignancy with significant morbidity and mortality rates. Targeted therapy has emerged as a crucial treatment modality, aiming to inhibit tumor growth by specifically targeting molecular sites within cancer cells. Understanding the research landscape is essential for advancing therapeutic strategies and improving patient outcomes.

Data Highlights

Key Findings

• The annual publication volume for targeted therapy in BC has shown an upward trend over the past three decades.
• English publications have a faster growth rate compared to Chinese publications.
• The USA, University of Texas System, and Dinney CPN are leading contributors in English publications.
• Research hotspots include keywords such as "phase-ii trial", "cell line", and "EGF receptor".
• Chinese publications are led by the Second Hospital of Jilin University and Wang JS.
• Future research will focus on drug management for metastatic BC and overcoming drug resistance.

Clinical Implications

The findings indicate a growing interest in targeted therapies for bladder cancer, which may influence future research directions and collaborations. Understanding these trends can help clinicians stay informed about emerging treatment modalities.

Conclusion

This bibliometric analysis provides valuable insights into the evolving landscape of targeted therapy research in bladder cancer, emphasizing the need for continued exploration and collaboration in this field.

Related Resources & Content

1. Focus on Emerging Therapies for Non-Muscle Invasive Bladder Cancer, World Journal of Urology, 2009 -- New treatments in NMIBC
2. A molecular landscape tracking the progression of non-muscle invasive bladder cancer, World Journal of Urology, 2026 -- Molecular landscape of NMIBC
3. Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis, Frontiers in Oncology, 2026 -- Diagnosis of VBC
4. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma, ScienceDirect, 2024 -- ESMO guidelines
5. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024, PubMed -- NCCN updates
6. Frontiers in Immunology — Editorial: Beyond therapeutic innovation in genitourinary cancers: the unmet need for biologically driven patient selection
7. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
8. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
9. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma - ScienceDirect
10. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024 - PubMed
11. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma | New England Journal of Medicine
12. Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial - PubMed
13. Enfortumab Vedotin With or Without Pembrolizumab in Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis - PMC
14. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer | New England Journal of Medicine
15. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer - Uroweb
16. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine